Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation - Wikidata - wikimedia - TriplyDB

Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation

Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation

http://www.wikidata.org/entity/Q34982068

about

Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma External beam radiotherapy for unresectable hepatocellular carcinoma Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review A nonrandomized cohort and a randomized study of local control of large hepatocarcinoma by targeting intratumoral lactic acidosis Increased level of nucleolin confers to aggressive tumor progression and poor prognosis in patients with hepatocellular carcinoma after hepatectomy Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis Perfusion reduction at transcatheter intraarterial perfusion MR imaging: a promising intraprocedural biomarker to predict transplant-free survival during chemoembolization of hepatocellular carcinoma Research reporting standards for radioembolization of hepatic malignancies.Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times.Intraprocedural transcatheter intra-arterial perfusion MRI as a predictor of tumor response to chemoembolization for hepatocellular carcinoma Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non-three-dimensional Imaging Markers Radioembolization for primary and metastatic liver cancer.Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver.Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis.Transcatheter intraarterial therapies: rationale and overview External beam radiotherapy for unresectable hepatocellular carcinoma.Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression.Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome.Evaluation of cancer treatment in the abdomen: Trends and advances.Interreader and inter-test agreement in assessing treatment response following transarterial embolization for hepatocellular carcinoma Chemoembolization and radioembolization for hepatocellular carcinoma.Renal Cell Carcinoma Metastatic to the Liver: Early Response Assessment after Intraarterial Therapy Using 3D Quantitative Tumor Enhancement Analysis.Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach.Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib.Imaging of hepatocellular carcinoma and image guided therapies - how we do it.Treatment of intermediate-stage hepatocellular carcinoma.Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment.Assessing tumor response after loco-regional liver cancer therapies: the role of 3D MRI.Hepatic imaging following intra-arterial embolotherapy.In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?Intra-arterial therapies for liver cancer: assessing tumor response.Interventional Oncology Service Development.Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection.Clinical significance of AFP and PIVKA-II responses for monitoring treatment outcomes and predicting prognosis in patients with hepatocellular carcinoma.Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation.Survival benefit of radioembolization for inoperable hepatocellular carcinoma using yttrium-90 microspheres.Angiosomal radiopathologic analysis of transarterial radioembolization for the treatment of hepatocellular carcinoma.Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?

P2860

Q24186130-5C6A8314-7475-429E-8950-FBD049ED2A09 Q24194017-2D30B70D-E535-4BB3-A479-9C99DFF088C4 Q24194024-D2263B0F-12B6-434B-AF35-2413F8C2B381 Q26743603-B38A9644-47C9-474E-AD27-394F2C5678A6 Q28831507-A963D20C-722A-451B-84DA-9C8B5368C609 Q34253205-EF0EEA7F-38C1-49D7-BAF2-27A248153B7B Q34680081-7DCE3818-5899-4DF0-BB75-81E6E21A78C4 Q34681150-140CC88E-7250-4CFC-A3C4-027A9C3C531C Q35111887-7A82C959-2DE9-475C-A11C-A8F3DEBBFF2D Q35154103-DA222D79-3A29-4150-B8FC-C59791CF1A44 Q35203257-0F7F4DF4-2F46-4AB2-B9E1-480CF329A110 Q35537007-EA4C8805-69C9-44D7-A254-06A937D787C7 Q35564038-F422AE55-925D-423D-82EA-7A67874A73D7 Q35691040-7048BD10-FD8C-4E80-A759-A90DE846BBCA Q35815482-3F7BEE90-3F29-4EF0-AA8D-3CB85E11790F Q35894925-242B9CAE-F68C-4D61-B45A-72DF0555CFD0 Q36104314-E7C31955-138B-4393-85D5-1D7A2494EB81 Q36299237-3049EDE8-5EB5-46AA-96AC-ACE17DAFDD81 Q36481071-D41C01EE-F3A6-4B5F-8251-5B996F81CD53 Q36773155-258D32F1-041B-461B-A004-F84E62F1FD65 Q36832118-82D2E7B3-A7CB-4B89-92C1-9737B994807A Q37143017-1B3A1C7D-698F-43B6-BCEF-D7BB66EAA05B Q37238192-BF21742A-5F97-48D7-895E-68922A689569 Q37253841-F1E98A3F-8687-46F5-8A7A-ED701BE09072 Q37348887-1F302D8D-743D-4CF0-BDEE-B5A1833279A0 Q37396802-448EF8B4-C479-41FF-96D8-E6F0764136AC Q37680183-6F06FD40-0F30-4989-903C-F824F60E8945 Q38236876-72B14C22-8D06-4B28-A0C1-69399233B288 Q38265024-16837DDF-2AC4-4B4F-B9AB-C35C7D966082 Q38265114-37C924D2-83F0-4BE7-9F67-CCB22DE9F8BE Q38716483-66C70A84-5DE4-4955-A71C-1140800A9AD2 Q38984450-62154446-82CB-4D13-9979-E3571C0F236F Q39041266-1AC38940-235D-44B3-A5ED-69AC686B3B19 Q39349682-6EC87B0F-D1AE-4B6E-B06A-B11CEB90B914 Q40091767-F8E9C6CD-B0B6-4839-9D10-2BCB84B92EEE Q41859517-658445C8-C872-4EB0-B90A-37F69B35E5E5 Q42237455-DCA9527D-DC94-4874-A2DE-D3D50AB4D6A3 Q43961233-BE9ABE65-3048-40FB-B4A2-CAF449A03A59 Q48156557-BCBBAB90-0084-4769-A8D4-3BFC8EE9BADD Q50223119-FAEB3FBA-3BDC-4D5C-B946-8351582A63C6

P2860

Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation

http://www.wikidata.org/entity/Q34982068

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Role of the EASL, RECIST, and ...... iologic-pathologic correlation

@ast

Role of the EASL, RECIST, and ...... iologic-pathologic correlation

@en

Role of the EASL, RECIST, and ...... iologic-pathologic correlation

@nl

type

label

Role of the EASL, RECIST, and ...... iologic-pathologic correlation

@ast

Role of the EASL, RECIST, and ...... iologic-pathologic correlation

@en

Role of the EASL, RECIST, and ...... iologic-pathologic correlation

@nl

prefLabel

Role of the EASL, RECIST, and ...... iologic-pathologic correlation

@ast

Role of the EASL, RECIST, and ...... iologic-pathologic correlation

@en

Role of the EASL, RECIST, and ...... iologic-pathologic correlation

@nl

P1433

Q34982068-AD72C1E0-517E-4260-9208-E9DCDD7BB09C

P1476

Q34982068-9CED45E9-EA55-45ED-B28B-3065C66CC883

P2093

Q34982068-06BD89E1-18B6-4E3E-8293-08973CD3A859

Q34982068-27ABD7A9-BA3A-4EB9-A9FE-2841344026B6

Q34982068-3E133CD5-AB68-4680-BB58-D6889F2E1B38

Q34982068-44B557D5-FFE3-4048-B64F-84029D6422A0

Q34982068-6285F458-C844-488B-97D6-8D3582F6B932

Q34982068-705C6D1C-36D6-4110-95B8-C623A7614C3A

Q34982068-72664C1C-E8F2-4ADE-8C8E-84BFF5F25C64

Q34982068-84336E93-12CA-4D70-B78F-2273452621CB

Q34982068-9033B503-92B0-42C0-AD23-FF31F5C905FD

Q34982068-95975D25-E1F0-4FB4-86E9-2B1B0929DC11

P2860

Q34982068-0322E57E-0EC6-46FC-935C-8C7EE667A878

Q34982068-0E3C18FB-27EB-4445-8D41-6E87B7B63967

Q34982068-18A20E26-16DC-45EF-97C2-0B971A27FCD9

Q34982068-2398A872-70EE-40CF-BADD-4D2B8DC38E3E

Q34982068-27E61241-3C18-48DB-AE11-9BCA44B5A4FD

Q34982068-2D2F5B20-CD86-4D3C-882A-91D44309D51D

Q34982068-37A4CC28-C41C-4999-98B0-E91B22EB3861

Q34982068-427E6913-FF6A-42DB-908A-292A2E4A0262

Q34982068-4546FA4A-4FCF-4612-945D-1916BE78CAF7

Q34982068-47E8DBA6-F18C-4BCA-AF8D-0A4FD990D2C4

P304

Q34982068-E8A1CCE7-04BA-4A98-A0E3-CB9CC353DFBA

P31

Q34982068-4BA94D8C-DFB0-415A-AA9B-54F988F2B251

P356

Q34982068-C2212A83-4E8E-431D-B854-B7F71C11FBF1

P433

Q34982068-154A3551-839A-4087-BEC7-CE7A2076E3D1

P478

Q34982068-DE47853B-BE2C-4091-9303-66329FCF411A

P50

Q34982068-45AF4CD5-32FC-476A-9201-F4ED4AAD51D9

Q34982068-5B78CB87-B94C-4324-9A26-0751936B8222

Q34982068-E4198718-D032-446D-833E-F0E647891156

P577

Q34982068-4D05A67E-C60E-430E-AD21-6BDBC7097317

P5875

Q34982068-9A1152DA-9873-40BF-98EC-D7D6F81D59FA

P698

Q34982068-0B957410-490A-4DD0-AC3F-6540D91A618B

P921

Q34982068-A2B3D67F-4D66-417E-9D3F-D0FC8FD4A3DB

P932

Q34982068-6F6B462C-D81F-44B1-A0EB-4320E464723E

P356

J.JHEP.2010.10.004

P1433

Journal of Hepatology

P1476

Role of the EASL, RECIST, and ...... iologic-pathologic correlation

@en

P2093

Al B Benson

http://www.w3.org/2001/XMLSchema#string

Ed Wang

http://www.w3.org/2001/XMLSchema#string

Frank H Miller

http://www.w3.org/2001/XMLSchema#string

Kent T Sato

http://www.w3.org/2001/XMLSchema#string

Khairuddin Memon

http://www.w3.org/2001/XMLSchema#string

Laura M Kulik

http://www.w3.org/2001/XMLSchema#string

Mary F Mulcahy

http://www.w3.org/2001/XMLSchema#string

Michael Abecassis

http://www.w3.org/2001/XMLSchema#string

Paul Nikolaidis

http://www.w3.org/2001/XMLSchema#string

Ramona Gupta

http://www.w3.org/2001/XMLSchema#string

P2860

The Measurement of Observer Agreement for Categorical Data

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Sorafenib in advanced hepatocellular carcinoma

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Yttrium-90 microspheres: radiation therapy for unresectable liver cancer

The meaning and use of the area under a receiver operating characteristic (ROC) curve

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Management of hepatocellular carcinoma

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

P304

695-704

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JHEP.2010.10.004

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P50

Vanessa L. Gates

P577

2010-10-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49673418

http://www.w3.org/2001/XMLSchema#string

P698

21147504

http://www.w3.org/2001/XMLSchema#string

P921

Alþjóðaheilbrigðismálastofnunin

P932

3094725

http://www.w3.org/2001/XMLSchema#string